Adicet Bio to Participate in Upcoming Investor Conferences
Adicet Bio (ACET), a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies, announces its participation in three major investor conferences in November 2024. The company will attend the Truist Securities BioPharma Symposium in New York for 1x1 meetings, the Guggenheim Securities Healthcare Innovation Conference in Boston featuring a fireside chat, and the Jefferies London Healthcare Conference. CEO Chen Schor will lead fireside discussions at both the Guggenheim and Jefferies events. Live webcasts will be available on Adicet's website with 30-day replay access.
Adicet Bio (ACET), un'azienda biotecnologica in fase clinica focalizzata sulle terapie allogeniche con cellule T gamma delta, annuncia la sua partecipazione a tre importanti conferenze per investitori nel novembre 2024. L'azienda parteciperà al Truist Securities BioPharma Symposium a New York per incontri uno a uno, al Guggenheim Securities Healthcare Innovation Conference a Boston, che presenterà una discussione informale, e al Jefferies London Healthcare Conference. Il CEO Chen Schor guiderà le discussioni informali sia all'evento Guggenheim che a quello di Jefferies. Saranno disponibili trasmissioni in diretta sul sito web di Adicet con accesso alla registrazione per 30 giorni.
Adicet Bio (ACET), una empresa de biotecnología en etapa clínica centrada en terapias con células T gamma delta alogénicas, anuncia su participación en tres importantes conferencias para inversores en noviembre de 2024. La empresa asistirá al Truist Securities BioPharma Symposium en Nueva York para reuniones 1x1, al Guggenheim Securities Healthcare Innovation Conference en Boston, que contará con un chat informal, y a la Jefferies London Healthcare Conference. El CEO Chen Schor liderará las discusiones informales en los eventos de Guggenheim y Jefferies. Se transmitirán webcasts en vivo en el sitio web de Adicet, con acceso a la repetición durante 30 días.
Adicet Bio (ACET)는 모든ogeneic gamma delta T 세포 치료에 중점을 둔 임상 단계 생명공학 회사로, 2024년 11월에 개최되는 3개의 주요 투자자 회의에 참가한다고 발표했습니다. 회사는 Truist Securities BioPharma Symposium에 참석하여 1x1 미팅을 진행하고, Guggenheim Securities Healthcare Innovation Conference에서는 파이어사이드 채팅이 열리며, Jefferies London Healthcare Conference에도 참여할 예정입니다. CEO인 Chen Schor는 Guggenheim과 Jefferies 행사에서 파이어사이드 토론을 주도할 것입니다. Adicet의 웹사이트에서는 생중계가 제공되며, 30일 간 재생할 수 있는 옵션이 있습니다.
Adicet Bio (ACET), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies cellulaires allogéniques à base de cellules T gamma delta, annonce sa participation à trois grandes conférences pour investisseurs en novembre 2024. La société assistera au Truist Securities BioPharma Symposium à New York pour des rencontres individuelles, à la Guggenheim Securities Healthcare Innovation Conference à Boston, qui comprendra une discussion informelle, et à la Jefferies London Healthcare Conference. Le CEO Chen Schor animera des discussions informelles lors des événements Guggenheim et Jefferies. Des retransmissions en direct seront disponibles sur le site web d'Adicet, avec un accès à la rediffusion pendant 30 jours.
Adicet Bio (ACET), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf allogene gamma delta T-Zelltherapien konzentriert, gibt seine Teilnahme an drei wichtigen Investorenkonferenzen im November 2024 bekannt. Das Unternehmen wird am Truist Securities BioPharma Symposium in New York für 1x1-Gespräche teilnehmen, an der Guggenheim Securities Healthcare Innovation Conference in Boston mit einem informellen Gespräch teilnehmen und zur Jefferies London Healthcare Conference kommen. CEO Chen Schor wird die informellen Diskussionen auf sowohl der Guggenheim- als auch der Jefferies-Veranstaltung leiten. Live-Webcasts werden auf der Website von Adicet verfügbar sein, mit 30-tägigem Zugriff auf die Aufzeichnungen.
- None.
- None.
Details of the events are as follows:
Truist Securities BioPharma Symposium, November 7, 2024,
- Members of management will be available for 1x1 meetings on November 7, 2024
Guggenheim Securities Healthcare Innovation Conference, November 11-13, 2024,
- Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on November 12, 2024 at 3:00 p.m. ET
Jefferies London Healthcare Conference, November 19-21, 2024,
- Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on November 19, 2024 at 12:30 p.m. BST
The live audio webcasts of the fireside chats can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101153157/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
What investor conferences will Adicet Bio (ACET) attend in November 2024?
When is Chen Schor's fireside chat at the Guggenheim Healthcare Conference 2024?
Where can investors watch Adicet Bio's (ACET) conference presentations?
